Navigation Links
UMass Medical School's Craig Mello elected to American Academy of Arts and Sciences
Date:4/30/2008

nsible for the transmission of genetic informationcan silence targeted genes. This process, RNAi offers astounding potential for understanding and manipulating the cellular basis of human disease, and is now the state-of-the-art method by which scientists can knock down the expression of specific genes to thus define the biological functions of those genes. Just as important has been the finding that RNAi is a normal process of genetic regulation that takes place during development, opening a new window on developmental gene regulation. RNAi has swept through laboratories around the world, changing the way many biomedical researchers work. Outside UMMS laboratories, companies at the forefront of pharmaceutical innovation are using RNAi technology to aid in their development of treatments for disease. At UMMS, researchers are taking full advantage of RNAi technology to speed investigation into a variety of diseases such as diabetes, cancer, ALS and HIV/AIDS.

Mello, a Howard Hughes Medical Institute Investigator, holds his BS in biochemistry from Brown University and his PhD in Cellular and Developmental Biology from Harvard University. He was a postdoctoral fellow at the Fred Hutchinson Cancer Research Center before coming to Worcester to join UMMS in 1995. He is also a 1995 Pew Scholar in the Biomedical Sciences. His work so inspired philanthropists John F. Jack Blais and wife Shelley that they contributed a $3 million gift in October 2003 to establish the Blais University Chair in Molecular Medicine to assist Mello in his future research endeavors. In addition to being honored with election to the AAAS and the National Academy of Science (Fire in 2004 and Mello in 2005), Mello and Fires discovery has garnered numerous honors, including the National Academy of Sciences Award in Molecular Biology in 2003. That same year, they were awarded the prestigious Wiley Prize in the Biomedical Sciences. Their RNAi finding was named the 2002 Breakthrough of the Ye
'/>"/>

Contact: Alison Duffy
alison.duffy@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal
2. UMass Medical School researchers receive $8.5M grant award to fight AIDS
3. American College of Medical Genetics makes genetic testing recommendations in new policy statement
4. Medical College researchers find dinosaur clues in fat
5. Science expands Science Signaling, featuring research related to medical advances, and more
6. Journal of Womens Health named official journal of American Medical Womens Association
7. Chloroform provides clue to 150 year old medical puzzle
8. Springer expands publishing partnership with the Biomedical Engineering Society
9. The top 5 ways medical physics has changed health care
10. Analysis calls for medical device information to better serve patients and doctors
11. 2 federal public health grants awarded to Weill Cornell Medical College
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):White, but not pure 2White, but not pure 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6The Lupus Foundation of America Applauds New Legislation that Caps Out of Pocket Drug Costs 53992 1The Lupus Foundation of America Applauds New Legislation that Caps Out of Pocket Drug Costs 53992 2Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 1Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 2Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 3Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 4Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 5Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 6WebMD to Present at the Canaccord Adams 29th Annual Global Growth Conference 53982 1
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4